Research Topics
| M SchwenkglenksSummaryAffiliation: University of Basel Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
A model of osteoporosis impact in Switzerland 2000-2020Matthias Schwenkglenks
ECPM Executive Office, University Hospital, 4031, Basle, Switzerland
Osteoporos Int 16:659-71. 2005..Corresponding absolute fracture numbers will rise by 36%, 31%, and 23%. Related direct medical inpatient costs are predicted to increase by 33%; however, this estimate is subject to uncertainty due to limited availability of input data...- Costs of asthma in a cohort of Swiss adults: associations with exacerbation status and severityMatthias Schwenkglenks
Hirslanden Research, Zurich, Switzerland
Value Health 6:75-83. 2003..This article will address the effect of exacerbation status, disease severity (defined by medication required), and other variables on resource use and costs for asthma in Switzerland in 1996 to 1997... - Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatmentMatthias Schwenkglenks
European Center of Pharmaceutical Medicine, University of Basel, University Hospital, Basel, Switzerland
Support Care Cancer 14:901-9. 2006..The aims of this study were to assess chemotherapy treatment characteristics, neutropenic event (NE) occurrence and related risk factors in breast cancer patients in Western Europe... - Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia StudyMatthias Schwenkglenks
European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
Support Care Cancer 19:483-90. 2011.... - Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarctionMatthias Schwenkglenks
Institute of Pharmaceutical Medicine ECPM, University of Basel, Basel, Switzerland
Heart 98:544-51. 2012.... - Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasonsPatricia R Blank
Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland
BMC Public Health 8:272. 2008.... - Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysisSibylle Loibl
German Breast Group, Neu Isenburg, Germany
BMC Cancer 11:131. 2011..Chemotherapy dose delay and/or reduction lower relative total dose intensity (RTDI) and may affect short- and long-term outcome of metastatic breast cancer (MBC) patients... - Simulation-based cost-utility analysis of population screening-based alendronate use in SwitzerlandM Schwenkglenks
European Center of Pharmaceutical Medicine, University of Basel, ECPM Research, c o ECPM Executive Office, University Hospital, 4031 Basel, Switzerland
Osteoporos Int 18:1481-91. 2007.... - Economic efficiency of gate-keeping compared with fee for service plans: a Swiss exampleMatthias Schwenkglenks
ECPM Research, c o ECPM Executive Office, University Hospital, CH 4031 Basle, Switzerland
J Epidemiol Community Health 60:24-30. 2006..The aim of this study was to assess to what extent lower costs in a gate-keeping plan compared with a fee for service plan were attributable to more efficient resource management, or explained by risk selection... - Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromesMatthias Schwenkglenks
Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
Value Health 14:24-33. 2011.... - Epidemiology and costs of gastroesophageal reflux disease in Switzerland: a population-based studyMatthias Schwenkglenks
Soz Praventivmed 49:51-61. 2004..Assessment of the prevalence, health care resource use and cost of gastroesophageal reflux disease in Switzerland... - Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy deliveryMatthias Schwenkglenks
Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
J Hematol Oncol 3:27. 2010..The aim of this analysis was to assess the impact of chemotherapy-induced neutropenia (CIN) on ABVD chemotherapy delivery in HL patients... - Trastuzumab beyond progression: a cost-utility analysisK W Matter-Walstra
European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
Ann Oncol 21:2161-8. 2010..The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity... - Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trialYuki Tomonaga
European Center of Pharmaceutical Medicine, University of Basel, 4051 Basel, Switzerland
BMC Fam Pract 12:12. 2011..The aim of this study is to analyse the diagnostic accuracy of POCT in primary care... - Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemiaT D Szucs
Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
Oncology 81:45-9. 2011..The economic implications of adding i.v. iron to ESA treatment are less well investigated. Published randomized controlled trials do not provide sufficient data for a comprehensive cost-effectiveness analysis... - Determinants of costs and resource utilization associated with open heart surgeryE Sokolovic
Department of Medical Economics, University Hospital, Zurich, Switzerland
Eur Heart J 23:574-8. 2002..05 for operation time, R(2)=0.565). CONCLUSIONS: These results suggest that both pre-operative (patient related) and intra-operative (therapy- and patient-related) variables are predictors of costs in cardiac surgical patients... - Direct medical costs of type 2 diabetes and its complications in SwitzerlandIrmgard Schmitt-Koopmann
Division of Medical Economics, University Hospital, Zurich, Switzerland
Eur J Public Health 14:3-9. 2004..This represents a share of about 2.2% of the country's total healthcare expenditures. CONCLUSION: These findings demonstrate the high economic importance of type 2 diabetes and its complications in Switzerland... - Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory GroupNicole Blijlevens
Department of Hematology, University Medical Center St Radboud, PO Box 9101 6500 HB Nijmegen, The Netherlands
J Clin Oncol 26:1519-25. 2008.... - Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001Menga S Sandoz
University of Zurich, Switzerland
Swiss Med Wkly 134:448-58. 2004..ESRD costs are CHF 215 per patient per day. CONCLUSIONS: The prevalence of ESRD in patients with type 2 DM in Switzerland was 73.0 per million inhabitants in 2001. The costs of this avoidable late complication are considerable... - Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspectiveThomas D Szucs
Institute of Social and Preventive Medicine, University of Zurich, Gloriastrasse 18a, CH 8006 Zurich, Switzerland
Cardiovasc Drugs Ther 20:193-204. 2006..The EPHESUS pharmacoeconomic analysis was performed to evaluate the cost-effectiveness of eplerenone in the Swiss setting... - Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME)Jacques Claude
Division of Cardiology, University Hospital, CH-4031 Basel, Switzerland
Eur Heart J 25:2195-203. 2004..Costs should not be an argument against invasive management of elderly patients with chronic angina... - The economic efficiency of amlodipine in the treatment of coronary atherosclerosis--an analysis based on the PREVENT studyGieri Cathomas
Medical Department, Hirslanden Research, Zurich, Switzerland
Cardiovasc Drugs Ther 16:61-6. 2002..The cost-effectiveness of amlodipine treatment is approximately CHF 14,650 per life-year gained. CONCLUSION: The administration of the calcium antagonist amlodipine in CHD patients is cost-effective... - Self-treatment and self-medication of Swiss primary care physicians: a cause for concern?Matthias Schwenkglenks
Swiss Med Wkly 137:105-6. 2007